Beyond ICANS: Cellular and Molecular Mechanisms Linking CAR T-Cell Therapy to Long-Term Neurocognitive Outcomes
Open Access
Abstract
Chimeric antigen receptor (CAR) T-cell therapy can cause acute immune effector cell-associated neurotoxicity syndrome (ICANS), but its delayed neurological and long-term cognitive effects remain incompletely understood. Existing reviews primarily address clinical syndromes or cognitive assessment. This narrative review provides a cross-timescale synthesis of preclinical, neuropathological, biomarker, imaging, and longitudinal clinical evidence linking systemic immune activation, neurovascular interfaces, and central nervous system (CNS) cellular responses. Human studies associate acute ICANS with endothelial and barrier dysfunction, compartmentalized inflammation, and selected astroglial or neuroaxonal injury markers. Persistent microglial reactivity, oligodendroglial alterations, and impaired neurogenesis have predominantly been demonstrated in mice; related human transcriptomic observations derive from CNS-tumor tissue and do not establish persistent injury in hematological CAR T-cell recipients. Prospective clinical cohorts show heterogeneous, often recovering cognitive trajectories rather than uniform long-term deterioration. Acute ICANS, delayed non-ICANSs, and longer-term cognitive outcomes are clinically distinguishable, although their biological separation remains incompletely established. Available treatment studies address predominantly acute toxicity and do not demonstrate prevention of persistent cognitive impairment. We propose testable neurovascular-to-glial and neuronal pathways and a baseline-anchored, multimodal longitudinal framework to connect biological responses and recovery with domain-specific cognitive outcomes.Keywords
Funding Information
- Else Kröner-Fresenius-Stiftung
This publication has 77 references indexed in Scilit:
- Patient preferences for treatment‑free intervals in multiple myeloma: mixed‑methods insights on monitoring trade‑offs and supportive care improvementsSupportive Care in Cancer, 2026
- Prospective observational study of magnetic resonance imaging in anti-CD19 CAR T-cell-associated neurotoxicityJournal of Neurology, 2026
- Neuronal injury biomarkers GFAP and neurofilament light chains (NfL) are associated with neurotoxicity and endothelial dysfunction in adult patients treated with antiCD19 CART cellsClinical and Experimental Medicine, 2026
- Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphomaHemaSphere, 2025
- Immunotherapy-related cognitive impairment after CAR T cell therapy in miceCell, 2025
- EEG as a predictive biomarker of neurotoxicity in anti-CD19 CAR T-cell therapyJournal of Neurology, 2025
- The impact of divergent forms of social support on health-related quality of life in patients with multiple myeloma and its precursor statesJournal of Cancer Research and Clinical Oncology, 2024
- Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T ImmunotherapiesCell, 2020
- Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell TherapyTransplantation and Cellular Therapy, 2020
- Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapyAnnals of Neurology, 2019